Background: The aim of this study was to evaluate whether cytidine deaminase (CDA) polymorphisms 79A>C and 435C>T and/or CDA enzymatic activity influenced clinical outcome in 126 advanced non-small-cell lung cancer patients treated with gemcitabine-platinum-regimens.
introduction Double platinum-containing regimens represent the gold standard of treatment in advanced non-small-cell lung cancer (NSCLC).
Platinum/gemcitabine combination is one of the most used regimens in the clinical practice [1] , but large interindividual variability in clinical response and efficacy has been observed. Therefore, new biomarkers with predictive power to assess interpatient differences in clinical outcome are urgently warranted.
Several genetic and epigenetic alterations, such as gene mutations, amplification, polymorphic status or altered gene/ protein expression and activity, have been associated with gemcitabine chemosensitivity/resistance [2] . Not surprisingly, these include polymorphic and activity variants of cytidine deaminase (CDA) which play a key role in the metabolism of gemcitabine (2#,2#-difluorodeoxycytidine) to its inactive metabolite, 2#,2#-difluorodeoxyuridine.
Three single nucleotide polymorphisms (SNPs) in the CDAencoding gene, A79C (Lys27Gln), G208A (Ala70Thr) and C435T (Thr145Thr), have been correlated with differential in vitro activity and clinical outcome [3] [4] [5] [6] . However, these data are inconclusive and conflicting.
In our previous clinical study, we analysed the CDA A79C SNP in 65 advanced NSCLC patients treated with cisplatin/ gemcitabine and we observed a significant correlation with clinical benefit, longer time to progression (TtP) and overall survival (OS) [7] . Moreover, CDA A79A was significantly associated with grade ‡3 neutropenia/thrombocytopenia. This study did not include the analysis of CDA G208A (Ala70Thr) polymorphism, which displayed significant effects on gemcitabine pharmacokinetics and subsequent haematologic toxic effects in Japanese patients [6] , but was never reported in Caucasians.
Another study in 53 NSCLC Asian patients reported that the CDA C435C variant was associated with response and longer TtP after gemcitabine-carboplatin treatment [8] . Similarly, a recent report in Caucasian NSCLC patients showed a correlation between the CDA T435T genotype and poor response to platinum-gemcitabine chemotherapy and more severe nonhaematological toxicity [9] . In contrast, no relationship was found between CDA A79C and C435T genotypic status and toxic effects in a larger study examining the adverse events from three cohorts of patients, affected by different types of tumours, treated with gemcitabine alone or combined with other drugs. However, in the same study, the patients with reduced CDA activity experienced early severe gemcitabine-related toxic effects [10] , whereas another relevant finding of our study [7] was that CDA enzymatic activity was significantly lower in patients with CDA A79A genotype than in patients carrying the other variants.
A variety of possible confounding factors can explain these discrepancies, such as sample size, dose levels or lack of treatment uniformity [11] . Therefore, the present study was aimed at evaluating whether the CDA A79C and C435T SNPs, alone or combined, and/or the CDA enzymatic activity influenced clinical outcome and toxicity in a cohort of 126 NSCLC patients uniformly treated with gemcitabine-platinum-based regimens.
patients and methods patients
This study involved two medical oncology units: Livorno Civil Hospital (Livorno, Italy) and Parma University Hospital (Parma, Italy). Chemotherapy-naïve patients with histologically or cytologically proven NSCLC and measurable clinical stage IIIB or IV disease were evaluated. The other main inclusion and exclusion criteria are reported in the supplemental Methods (available at Annals of Oncology online).
The study was approved by the local hospital ethics committees and conducted according to Good Clinical Practice guidelines and with the World Medical Association's Helsinki declaration.
Informed consent for this study and related blood samples were obtained before chemotherapy treatment.
evaluation criteria
Pretreatment evaluation included medical history, physical examination, complete blood cell count with routine chemistry, and computed tomography (CT) scans of chest and abdomen.
Tumour response was evaluated by CT scan every three cycles. Responses were assessed using RECIST criteria, and the best overall response for each patient was reported. After the end of treatment, tumour radiological evaluation according to RECIST criteria was carried out every 2 months until evidence of progressive disease (PD).
Haematological and nonhaematological toxic effects were recorded at days 1 and 8 of every treatment course. The worst toxicity grade in all chemotherapy cycles was reported. Toxic effects were assessed using National Cancer Institute-Common Terminology Criteria (NCI-CTC 3.0 version). samples and DNA isolation DNA was isolated from blood (N = 126) and paraffin-embedded tumour (N = 38) samples, as reported in the supplemental Methods (available at Annals of Oncology online), using the microDNA kit (Qiagen, Germany). DNA yields and integrity were checked at 260-280 nm with NanoDropÒ 1000 Detector (NanoDrop Technologies, Wilmington, NC).
genotyping
The CDA A79C (rs#2072671) and C435T (rs#048977) polymorphisms were studied with TaqmanÒ probes-based assays (Applied Biosystems, Foster City, CA) using specific primers and probes from Applied (C__25472931_20, and C__7477307_30, respectively). PCR reactions were carried out using 20 ng of DNA in 5.94 ll deoxyribonuclease-ribonuclease free water, with 6.25 ll of TaqMan Universal PCR Master Mix and 0.31 ll of primers and probes. After thermal cycling, the ABI Prism 7500HT instrument determined the allelic content by reading the generated fluorescence with SDS 2.0 software [12] .
analysis of CDA enzymatic activity CDA activity was measured in blood samples, by high-performance liquid chromatography (HPLC), as described previously [7] and reported in the supplemental Methods (available at Annals of Oncology online).
statistical analysis
Demographic and clinical information were compared across genotype, using Pearson's v 2 tests. Treatment activity was analysed in terms of objective response rate and clinical benefit (objective responses plus stable diseases). The Kaplan-Meier method was used to plot TtP and OS, and the log-rank test was used to compare curves in univariate analysis. The prognostic variables of TtP and OS in univariate analysis were included in multivariate analysis using Cox proportional hazards model. Logistic regression was carried out to determine the associations between CDA activity and therapy responsiveness, calculating the odds ratio (OR) with 95% confidence intervals (CIs). When a significant P value was found, receiver operating characteristic (ROC) curves were computed in order to find a cut-off value, while the appropriate adjustment for multiple testing and the false-positive report probability (FPRP) of significant associations were further investigated according to Bonferroni correction and Wacholder's method [13] . The analysis of the samples was done in a blinded fashion and related to clinical outcome.
Further details on the methods and statistics are provided in the supplemental Methods (available at Annals of Oncology online).
results

patients' characteristics
From November 2006 to February 2009, a total of 126 consecutive Caucasian patients, affected by advanced NSCLC, were evaluated for this study, including 65 patients from our previous study [7] . The majority of patients had stage IV (85.7%), while 18 (14.3%) had stage IIIB disease ( Table 1) . The median follow-up for living patients was 25 months (range 10-48 months). Response rate was 25%; median TtP was 6.0 months (95% CI 4.9-7.1) and the median OS was 10.0 months (95% CI 7.3-12.7). Data on outcome according to clinical characteristics are reported in the supplemental Table S1 (available at Annals of Oncology online).
genotype information
Genotyping was successfully carried out in the vast majority of DNA samples (Table 2) . No discrepancies were observed in the samples analysed in duplicate (10%), and all the genotyping data were included in the final analysis.
No linkage disequilibrium was detected (r 2 = 0.056) between the CDA A79C and CDA C435T polymorphisms, whereas both polymorphisms followed Hardy-Weinberg equilibrium, and genotypes frequencies were comparable with those reported in Caucasian populations in NCBI/NCI-SNP500 databases [7] . No correlations were found between genotypes and tumour histology (e.g. 9 of the 12 patients carrying the CDA C79C genotype had adenocarcinoma versus 50 of 77 patients carrying the CDA A79A or A79C genotype; P = 0.72). Similarly, no significant correlations were detected between genotypes and age, performance status (PS), gender or stage (data not shown).
correlation between polymorphisms and clinical outcome
No significant correlations were observed between CDA genotypes and response, whereas a trend towards a significant association (P = 0.10, Pearson's v 2 two-sided test) was observed by grouping patients with clinical benefit versus patients without clinical benefit. In particular, 75.9% of the patients carrying the CDA A79A or A79C genotype experienced a clinical benefit versus 56.3% of CDA C79C patients.
At univariate analysis, the CDA A79C polymorphism was associated with differential TtP and OS. Significantly, longer TtP was observed in patients harbouring the CDA A79A (7.0 months, 95% CI 5.4-8.6) and A79C (6.0 months, 95% CI 4.5-7.5) genotype, in comparison with patients carrying the C79C variant who had a median TtP of 3.0 months (95% CI 1.6-4.4, P = 0.005). Similarly, patients with the C79C genotype had a worse prognosis, median OS, 5.0 months (95% CI 4.0-16.5) than patients with the A79A (14.0 months, 95% CI 8.4-19.6) and A79C (10.0 months, 95% CI 6.9-13.1) genotype (P = 0.004). Significant differences (P = 0.001) for both TtP and OS were also observed grouping patients carrying the CDA A79A + A79C versus C79C patients (Table 2 and Figure 1A ).
The CDA C435T polymorphism revealed a trend towards a significant association with both TtP (P = 0.098) and OS (P = 0.079). Patients carrying the CDA C435C, C435T and T435T variants had median TtP of 5.0 (95% CI 3.5-6.5), 6.0 (95% CI 3.9-8.1) and 2.0 months (95% CI 0.6-4.3), respectively. Similarly, a shorter survival (5.0 months, 95% CI 2.0-8.0) was observed in patients harbouring the CDA T435T genotype, in comparison with patients carrying the C435C who had a median OS of 10.0 months (95% CI 6.8-13.2), identical to the heterozygote OS of 10.0 months (95% CI 5.5-14.5). The grouped analysis of CDA C435C + C435T versus T435T patients showed a longer survival for patients carrying at least one C allele (Table 2 and Figure 1B) .
Because CDA A79C and CDA C435T might have an additive effect on CDA, we further explored the effect of combined 'riskgenotype'. These combinations were analysed in 113 patients (patients not assessable for both polymorphisms were excluded). The deleterious alleles included CDA C79C and CDA T435T; in fact patients carrying the CDA C79C + T435T had a significantly shorter TtP and OS (Table 2 and Figure 1C) . We estimated the FPRP of the CDA A79C and CDA C435T original articles Annals of Oncology groups to be, respectively, 0.049 and 0.187, indicating noteworthiness. However, assuming that there were three independent tests, the Bonferroni-adjusted P value for OS remained significant for CDA A79C and for the combination of risk genotypes but not for CDA C435T.
correlation between CDA genotype and enzymatic activity
The analysis of CDA activity was successfully carried out in most samples (N = 124). There was no statistical difference in activity values according to adenocarcinoma versus epidermoid histology (P = 0.46), as well as gender, age or other clinical characteristics (data not shown).
The mean enzymatic activity in patients harbouring the wild type (CDA A79A) was 8963.9 6 6614.9 pmol/h/mg proteins, whereas in patients carrying CDA A79C and CDA C79C genotype, the mean CDA activities were 11686.5 6 9339.9 and 15450.6 6 10155.6 pmol/h/mg proteins, respectively (P = 0.009, Kruskal-Wallis test). Statistical analysis with the MannWhitney test also revealed a significant difference (P = 0.019) between CDA A79A + CDA A79C patients and carriers of the CDA C79C genotype (Figure 2A) .
In contrast, there were no statistically significant differences (P = 0.256) in CDA activity in patients with the CDA C435C, CDA C435T and CDA T435T genotypes (e.g. 9888.8 6 7789.7, 11954.7 6 9279.2 and 13955.8 6 9523.4 pmol/h/mg proteins, respectively), as well as grouping CDA C435C + CDA C435T versus CDA T435T patients (P = 0.121).
However, the 'risk-genotype' was associated with a significantly higher CDA activity (18368.5 6 10281.7 pmol/h/mg proteins) versus patients harbouring all the other genotypes (P = 0.039).
correlation between enzymatic activity and clinical outcome
The median CDA activity in all the 124 patients was 8243.6 (range 23.2-45566.3) pmol/h/mg proteins. Using this value as cut-off, patients with low-CDA activity had a significantly Figure 2B -C).
Low-CDA activity was also significantly associated with clinical benefit; 56 of the 61 patients (91.8%) with low-CDA activity achieved complete response, partial response or stable disease (SD) versus 30 out of 58 (51.7%) patients with high-CDA activity (P < 0.001).
Similarly, a significant difference between mean CDA activity (P = 0.007) was detected grouping patients with response (7641.3 6 5626.7 pmol/h/mg) versus patients with SD and PD (12447. 7 6 9360.6 pmol/h/mg proteins), as well as grouping patients with clinical benefit (9556.5 6 8502.8 pmol/h/mg) versus patients with PD (15440.5 6 8156.9 pmol/h/mg, P < 0.001).
CDA activity data were analysed continuously but considering the unsatisfactory AUC values for response (AUC = 0.67), the optimal cut-off value was not identified and the population was categorized according to median CDA activity value. However, ROC curves (supplemental Figure S1 , available at Annals of Oncology online) for response with this cut-off reported a sensitivity of 58.8% (95% CI 47.6-69.4) and a specificity of 73.3% (95% CI 54.1-87.7). Similar data were observed for clinical benefit: sensitivity of 63.9% (95% CI 53.8-75.2) and specificity of 84.4% (95% CI 67.2-94.7).
multivariate analysis
To evaluate the risk of disease progression and death, we carried out two Cox regression analyses entering all the variables significantly associated with TtP and OS in the univariate model.
Among polymorphisms (Table 3) , only the CDA C79C variant showed a significant association with both risk of progression and risk of death. Sex, PS and histology were not independent predictors of TtP and OS.
The Cox proportional hazards regression model used for the multivariate analysis confirmed the prognostic significance of CDA activity. In particular, low-CDA activity was significantly associated with reduced risk of death [hazard ratio (HR) 0.512, 95% CI 0.310-0.846, P = 0.009] as well with reduced risk of progression (HR 0.365, 95% CI 0.211-0.631, P < 0.001).
toxic effects
Toxic effects were recorded only on days 1 and 8 of every courses of chemotherapy. Of the 112 patients assessable for toxicity, 79 patients (70.5%) developed haematological toxicity (anaemia, neutropenia and/or thrombocytopenia), whereas 34 (30.4%) experienced vomiting, weakness, nausea, paraesthesia, tinnitus and/or hepatic/renal toxicity. No correlations were found between genotypes or activity and toxic effects as well as the number of administered chemotherapy cycles and frequency of dose reduction (Table 4) .
Toxic effects reported by grade (e.g. grade = 1-2 versus grade = 3-4) in the subgroups of patients with differential CDA genotypes and activities are listed in the supplemental Table S2 (available at Annals of Oncology online).
discussion
This study evaluated the impact of CDA polymorphisms and activity on outcome in advanced NSCLC patients and suggested that CDA enzymatic activity is a candidate biomarker of activity and efficacy in patients treated with platinum-gemcitabine regimens.
Recent advances in the treatment of advanced NSCLC have been obtained through the discovery of new-targeted drugs highly active in selected subgroup of patients [14, 15] . However, an actual challenge of research is also to find predictive biomarkers of efficacy for established chemotherapy regimens. The interindividual variability in toxicity also points original articles Annals of Oncology out to the need of novel pharmacogenetic markers to select patients before therapy.
A number of studies evaluated different biomarkers that predict response to current therapeutics and several genetic and epigenetic alterations, such as gene mutations, amplification, polymorphic status or altered gene/protein expression, have been associated with gemcitabine resistance and, among these possible predictive factors, germline polymorphisms emerged as an attractive target [2] .
The role of CDA SNPs was firstly highlighted by Sugiyama et al. [6] who reported that patients harbouring the CDA haplotype*3, e.g. the nonsynonymous G208A (Ala70Thr) SNP, had a lower clearance of gemcitabine and increased incidences of grade ‡3 neutropenia. However, the Ala70Thr variant has never been detected in Caucasians, whereas the minor allele frequency of CDA A79C polymorphism in the present study was >10%, making it a possible more clinically relevant polymorphism [5, [7] [8] [9] .
In our previous study in 65 NSCLC patients, the wild-type CDA A79A genotype was correlated with clinical benefit, longer TtP and OS and severe haematological toxicity. These data were partially concordant with the results reported by Farrell et al. In fact, data from 538 radically resected pancreatic cancer patients treated within the RTOG9704 randomized trial showed a correlation between the CDA A79A genotype with more severe haematological toxicity but not with treatment outcome [16] . In the present study, both the CDA A79C and CDA C435T SNPs were not predictive markers of activity or toxicity of treatment. However, we confirmed our previous observations that patients carrying the CDA A79A and the CDA A79C genotype had a statistically significant longer TtP and OS in comparison to patients with CDA C79C genotype. Furthermore, patients harbouring the CDA T435T genotype had a shorter OS in comparison to patients carrying the wildtype genotype or the heterozygous variant, and the group of patients with CDA A79A + T435T had significantly shorter TtP and OS.
These data are in partial agreement with the results reported by Okazaki et al. in 154 patients with potentially resectable pancreatic adenocarcinoma receiving neoadjuvant concurrent gemcitabine and radiation therapy with (N = 70) or without (N = 84) gemcitabine-cisplatin induction therapy. Six SNPs, including CDA A79C and C435T, showed weak associations with OS. However, when these SNPs were analysed in combination, a gene-dosage effect was observed, and as the number of at-risk alleles increased the OS decreased [17] . The discrepancies observed in the different pharmacogenetic studies might also stem from the complex and only partially elucidated system of genetic and epigenetic regulations of CDA gene that might alter the phenotypic activity of this enzyme.
Therefore, another important finding of the present study was that the enzymatic activity of CDA, as detected by HPLC, was correlated with both activity and efficacy of platinumgemcitabine therapy. In particular, patients with the lower levels of CDA activity reported an overall response rate of 37.7%, which was significantly higher than patients with high activity (13.8% of response rate; P = 0.006). Moreover, patients with low-CDA activity experienced a statistically significant longer TtP and OS in comparison to patients with high-CDA activity, which was confirmed to be an independent prognostic factor for worse TtP and OS at multivariate analysis.
To our knowledge, this is the first evidence about the predictive role of CDA enzymatic activity in terms of outcome in NSCLC patients treated with gemcitabine-based chemotherapy. A preliminary study in 40 pancreatic cancer patients reported a similar correlation between high-CDA activity and progression after gemcitabine-based treatments [18] .
These results can have important clinical applications, such as the modulation of the dose of gemcitabine according to CDA activity. Noteworthy, the HPLC analysis is a simple and costeffective test that only requires basic bench apparatus and standard reagents, which makes it easily transportable, also for essential methodological cross-validation [19] , in any laboratory.
Although missing a control population, the results of the present study are also important to hypothesize the predictive versus prognostic role of CDA enzymatic activity in this specific clinical setting. The primary end point was OS, which is the most objective outcome in this setting, but the additional data on response, clinical benefit and TtP suggest that CDA activity is predictive of better treatment activity.
In the pivotal study by Ciccolini et al. [10] , although without cases of toxic deaths or hospital admission for toxicity, patients with low-CDA activity experienced an early severe haematological toxicity. However, in the present study, the haematological and nonhematological toxicity was recorded only on days 1 and 8 of every courses of chemotherapy. Therefore, severe haematological toxicity, which eventually occurred on day 15, was not reported among the clinical data and we could not correlate these data with CDA genotypes and activity. However, the fact that we did not observe cases with a very low enzymatic activity of CDA could explain the absence of severe adverse events occurring in our population. In contrast, the correlation of CDA activity with efficacy factors (OS and TtP) might be the result of differential detoxification of the drug by both the liver and the tumour cells, which may occur also with smaller variations in enzymatic activity.
However, as reported in a recent review on this subject, 'considering the increasing evidence that indicates deregulations affecting CDA have a direct impact on this drug, CDA testing before gemcitabine administration should be considered as relevant strategy to optimize both treatment efficacy and safety' [19] .
In conclusion, although selected CDA polymorphisms confirmed their role in the prediction of TtP and OS, the analysis of CDA activity emerged as the strongest predictive marker of efficacy of platinum-gemcitabine-based chemotherapy and should be validated in a prospective clinical study. 
